Rhythm Pharmaceuticals, Inc.
General ticker "RYTM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $6.2B (TTM average)
Rhythm Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 15.1%.
Estimated limits based on current volatility of 2.3%: low 104.22$, high 109.10$
Factors to consider:
- Total employees count: 283 (+25.2%) as of 2024
- US accounted for 73.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Funding constraints, Regulatory and compliance, Clinical trial failure, Market competition, IP infringement
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [66.39$, 138.90$]
- 2026-12-31 to 2027-12-31 estimated range: [52.98$, 115.49$]
Financial Metrics affecting the RYTM estimates:
- Negative: with PPE of -35.7 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.19 < Shareholder equity ratio, % of 28.96 <= 42.57
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0.04 <= 0.80
- Positive: Interest expense per share per price, % of 0.29 <= 0.74
Short-term RYTM quotes
Long-term RYTM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $77.43MM | $130.13MM | $189.76MM |
| Operating Expenses | $261.79MM | $395.63MM | $381.77MM |
| Operating Income | $-184.36MM | $-265.50MM | $-192.02MM |
| Non-Operating Income | $0.24MM | $5.25MM | $-4.03MM |
| Interest Expense | $13.89MM | $20.60MM | $20.58MM |
| R&D Expense | $134.95MM | $237.96MM | $167.34MM |
| Income(Loss) | $-184.11MM | $-260.26MM | $-196.04MM |
| Taxes | $0.56MM | $0.35MM | $0.50MM |
| Net Income(Loss)* | $-184.68MM | $-260.60MM | $-196.54MM |
| Stockholders Equity | $169.76MM | $21.73MM | $139.07MM |
| Inventory | $8.62MM | $18.74MM | $25.75MM |
| Assets | $332.75MM | $392.27MM | $480.20MM |
| Operating Cash Flow | $-136.16MM | $-113.88MM | $-115.67MM |
| Capital expenditure | $0.05MM | $0.00MM | $0.95MM |
| Investing Cash Flow | $-5.67MM | $-48.17MM | $-137.15MM |
| Financing Cash Flow | $74.37MM | $191.24MM | $217.96MM |
| Earnings Per Share** | $-3.20 | $-4.27 | $-3.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.